



ATTIRE

RANDOMISED CLINICAL TRIAL

The ATTIRE Trial is currently running at this hospital, Is your patient eligible??

What is it? A trial to investigate whether giving albumin to patients with advanced liver cirrhosis will reverse immune suppression and improve outcome from infection. (*Chief Investigator: Dr Alastair O'Brien, University College London*)

What does the trial involve? Patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) during of their admission (maximum of 14 days from randomisation). The dose will be administered to target a daily serum albumin of 35g/l



Is your patient eligible??

Inclusion Criteria

- All patients admitted to hospital with acute onset or worsening of complications of cirrhosis
- Age 18 years and over
- Predicted hospital admission ≥ 5 days (at trial enrolment), which must be within 72 hours of admission
- Serum albumin $<30\text{g/l}$ at screening
- Documents informed consent to participate (or consent given by a legal representative)

Exclusion Criteria

- Advanced hepatocellular carcinoma with life expectancy of less than 8 weeks
- Patients who will receive palliative treatment only during their hospital admission
- Pregnancy
- Known or suspected severe cardiac dysfunction
- Any clinical condition which the investigator considers would make the patient unsuitable for the trial
- The patient has been involved in a clinical trial of Investigational Medicinal Products (IMPs) within the previous 30 days that would impact on the patients participation in the trial
- Trial investigator unable to identify the patient (by NHS number)

If your patient may be eligible to take part in the trial or you have any questions about the trial please contact:

Site PI: _____

Study Team: _____

Or visit: www.attiretrial.com for further information